Stents in the Management of Heart Disease in Children

P Syamasundar Rao*
Division of Pediatric Cardiology, UT-Houston Medical School, Houston, Texas, USA

The editorials in previous issues of this Journal [1,2] addressed balloon valvuloplasty and angioplasty in pediatric practice and percutaneous occlusion of cardiac defects in children. In this editorial, the use of stents in the management of heart disease in children will be reviewed.

Percutaneous, transluminal angioplasty while effective in relieving vascular obstructive lesions in most cases, it does have limitations in that elastic recoil of vessel wall and intimal dissection may produce ineffective relief of obstruction. Stents exert radial forces to prevent elastic recoil of the vessel wall and may also compress dissection flaps against vessel wall, thus producing more effective relief of obstruction. Stents may also be helpful in keeping open naturally occurring lesions (for example ductus arteriosus or foramen ovale) or surgically created connections (for example Blalock-Taussig shunt).

Although the concept of stents was introduced by Dotter and his colleagues in 1960s, it is not until introduction of stainless steel mesh stents by Palmaz in 1980s did the stent technology became a reality. Clinical studies in late 1980s and early 1990s demonstrated that the stents are useful in the management obstructive lesions of coronary, iliac and renal arteries in adults. Application of the stent technology to pediatric patients followed [3].

Stents are classified based on the delivery mechanism, composition and configuration of the stent. Balloon-expandable and self-expandable types are available; balloon-expandable stents, mounted on balloons may be positioned across the site of obstruction and implanted by inflating the balloon. The diameter of the balloon determines the expanded diameter of the stent. This is the most commonly used stent in children because these stents may be further expanded to meet the needs of a growing child. Self-expandable stents on the other hand are restrained within a covering sheath and after positioning the stent in the desired location, withdrawal of the sheath uncovers the stent; the stent then assumes its original shape. Because of anticipated growth in children, self-expandable stents are used in a very limited manner in children. Stainless steel (316L) is the most common metal utilized in stents although platinum-iridium, Nitinol, cobalt-based alloys, titanium and tantalum have also been used. Because of lack of growth of stented segments, biodegradable materials may offer advantage. However, these are not currently available for pediatric patients. While several varieties of stent designs have been used, including slotted tube, mesh, coil-loop and ring, the slotted tube design or its variations are used in the majority of stents in clinical practice.

The usefulness of stents in treating obstructive lesions of the branch pulmonary arteries [4,5], systemic [6,7] and pulmonary [8] veins, aorta [9] and right ventricular outflow conduits [10] and maintaining the patency of ductus arteriosus [11-13], stenotic aorto-pulmonary collateral vessels [14,15] or surgically created but obstructed shunts [15,16] has been demonstrated. Extensive review of the techniques and results may be found in our previous publications on this subject [17-22].

Obstructive Lesions

Branch pulmonary artery stenosis

Because of poor results associated with surgical and balloon angioplasty of stenotic pulmonary arteries (PAs), balloon expandable stents introduced by Palmaz et al. [23], have been rapidly adopted [3,4,17,22,24-26] in their management. The indication for intervention [19,26] in unilateral obstructions is ipsilateral lung perfusion ≤ 35% on quantitative pulmonary perfusion scans and in bilateral obstructive lesions a right ventricular peak systolic pressure equal to or greater than 50% aortic systolic pressure. These criteria may be relaxed in the presence of pulmonary insufficiency. Long-segment lesions and older children are preferred for stenting whereas infants and younger children and discrete lesions may be dealt with balloon angioplasty alone.

Reduction in peak systolic pressure gradient across the branch PA sites, improvement in vessel diameter and better perfusion to ipsilateral lung were seen have following stent placement. Results from initial experience with stents in branch PAs is tabulated elsewhere [19] for the interested reader. Advances in the technique over the past two decades helped in reducing the profile of stent delivery sheaths and reduced the complication rate. Follow-up results are usually good, and re-dilation of the stent can be performed if restenosis occurs. Reduction in right ventricular (RV) to aortic pressure ratio in patients with biventricular circulation and increase in quantitative pulmonary perfusion by lung scans in unilateral branch PA stenosis are good indicators of success. Implantation of stents to relieve branch PAs is feasible, safe and effective. Currently intravascular stents are the chief mode of treatment for branch PAs inmost pediatric cardiology programs.

Coarctation of the aorta

Problems associated with surgical and balloon therapy of aortic coarctation prompted acceptance of stent therapy over the last two decades [9,19,22,26-49]. The indications for use stents are: 1) long segment coarctation, 2) associated hypoplasia of the isthmus or aortic arch, 3) tortuous coarctation with misalignment of proximal with distal aortic segment and 4) recurrent aortic coarctation or an aneurysm following prior surgical or balloon therapy [19]. Because the stents do not grow as children grow, most cardiologists limit use of stents to adolescents and adults. However, some cardiologists [50-53] advocate stents at early age. However, I personally do not advocate use of stents in young children with aortic coarctation [21,54].

Reduction of peak systolic pressure gradient and increase in the diameter of the coarcted segment are seen following stent deployment. In the initial series of 10 patients reported by Suarez de Lezo in 1995 [9], the peak systolic pressure gradient across the coarctation site
decreased (43 ± 12 vs. 2 ± 3 mmHg; p<0.001) and the ratio of isthmus/ descending aorta improved from 0.65 ± 0.14 to 1 ± 0.08 following the stent procedure. Similar results have been reported later by other investigators [9,19,22,26-49]; results from initial series are tabulated elsewhere [19] for the interested reader. Stent deployment was found effective in native coarctation as well as post-surgical and post-balloon recoarctation. Complications such as vessel disruption, displacement of stent, balloon rupture, loss of pulse, bleeding from puncture site and aneurysms have been reported, but are uncommon. The follow-up was incomplete in that it involved a limited number of patients and the duration of follow-up was short in most studies. Nevertheless, in some studies [33,35,37,48] the results of more than 20 patients at a mean follow-up of 2 years or longer were scrutinized. The systolic pressure gradients across the coarctation site remained low and systemic hypertension improved both in frequency and magnitude with resultant decrease in antihypertensive medication use. No evidence for significant rate of recoarctation, aneurysmal formation or stent fracture/displacement was observed, although no systematic or complete follow-up was achieved in the most studies. Residual or recurrent obstruction was present in a few patients and re-dilatation with larger balloons was successful. Suarez de Lezo et al. [33] performed detailed angiographic studies which revealed no detectable neointimal proliferation in 75% patients. In the other patients focal neointimal ridge formation was observed at ends of the stent causing mild restenosis. Segmental analysis of the aorta [33] revealed increase in non-stented portions of the aorta suggestive of normal growth.

Stent therapy is emerging as an attractive technique for management of native coarctation, post-surgical recurrent coarctation or aneurysm formation following surgical or balloon treatment as well as for long segment hypoplasia; this is particularly applicable for the adolescent and adult. Use of balloon-in-balloon (BIB) catheters to implant the stents is likely to reduce the complications. That the obstruction can be relieved both acutely and at follow-up is well shown in several published studies. The rate of recoarctation at follow-up is low and if that happens, re-expansion of the stent to address residual or recoarctation and growth related narrowing, appears feasible, safe and effective. Based on the currently available data, stent therapy for aortic coarctation is a preferred alternative to surgical or balloon treatment in the adolescent and young adult. Covered stents may have utility in highly selected patients with aortic coarctation, but are not currently approved in the US for addressing aortic coarctation.

Right ventricular outflow conduits

Obstruction may develop in bioprosthetic RV-to-PA conduits and this is thought to be secondary to calcific degeneration. This may necessitate surgical replacement of the conduit [55]. Balloon dilation may produce some improvement with nominal extension of the life span of the conduit, as reviewed elsewhere [55]. Therefore, several groups of cardiologists advocate use of stents to relieve these obstructions [10,24,56-61]. Potential for obstruction of the coronary arteries [62,63] during stent placement should be recognized and avoided. The indications for stent deployment that we use are elevated right ventricular systolic pressure >50% of systemic systolic pressure and/or right ventricular dysfunction. We continue to use balloon dilatation [55] in infants and young children initially and if not successful, stent may be implanted. The reason for this type of palliation is to postpone surgical replacement of the conduit.

Fall in peak systolic gradient, increase in conduit stenosis diameter and prolongation of conduit life span for varying time periods has been observed by most investigators [10,24,56-61]. It would appear that stent therapy is useful in prolonging the life of the RV/PA conduits and should be undertaken in an attempt to reduce total number surgical replacement of the conduits.

Stent therapy to open up: 1. native right ventricular outflow tracts of tetralogy of Fallot patients in the premature babies and young children as a bridge to later corrective surgery [64-66] and 2. Sano shunt obstructions in hypoplastic left heart syndrome babies [67-69] may accrue benefit to these infants. However, the practice with such interventions is limited. I will not address trans-catheter delivered pulmonary valve replacement [70-72] in this editorial.

Other lesions

While the experience is limited the stents have been utilized to address several other cardiac anomalies: 1. obstructed systemic veins after surgery such as atrial switch (Mustard or Senning) procedures for transposition of the great arteries, classical or bi-directional Glenn anastomosis, correction of partial anomalous pulmonary venous connection and cardiac transplantation or those that develop after trans-venous pacing leads or prolonged use of indwelling catheters and those that occur secondary to malignancy and radiation, 2. congenital pulmonary vein stenosis or pulmonary venous stenosis that develop after cardiac surgery such as Mustard or Senning procedures for transposition of the great arteries or repair of total anomalous pulmonary venous connection and 3. obstruction of ilio-femoral venous system.

Patency of Natural or Surgically Created Shunts

Stents have been found to be useful in maintaining patency of naturally occurring structures or surgically created but obstructed shunts. The ductus may be kept patent in the neonate with reduced pulmonary blood flow such as pulmonary atresia with intact ventricular septum, critical pulmonary stenosis and other complex heart defects with decreased pulmonary blood flow [11,12,73]. The ductus may also be kept open in hypoplastic left heart syndrome patients either as a bridge to transplantation [13] or as a part of hybrid procedure as an alternative of Stage I Norwood procedure [74]. Similarly a markedly restrictive foramen ovale may be kept patent in hypoplastic left heart syndrome or mitral atresia cases. Creation of an atrial septal defect by stenting the atrial septum in severe pulmonary hypertension cases, again as a bridge to transplantation may be useful. The pulmonary blood flow may be augmented by stenting stenotic aortopulmonary collateral vessels in patients with tetralogy of Fallot with multiple aorto-pulmonary collateral arteries and severe pulmonary oligemia [14,15]. Stenotic or completely occluded surgically created aorto-pulmonary shunts [16] such as Blalock-Taussig or Sano shunt may be re-opened by implanting stents into them.

Future Directions

Use of stents in infants and young children with aortic coarctation is not advisable because of growth issues. Development of biodegradable stents [75] which dissolve with time or growth stents [76] that can be re-expanded is likely to be beneficial in addressing optimal treatment of infant coarctation and should be investigated in future studies.

Implantation of stents in pulmonary venous stenotic lesions is fraught with problems because of development of stenosis of stents and therefore use of drug-eluding stents/balloons (impregnated with
drugs such as paclitaxel) may impede neo-intimal proliferation [77,78]. Studies to test this concept should be undertaken.

Finally, hybrid procedures to use of ductal stents along with surgical bilateral branch pulmonary artery banding in the palliation of hypoplastic left heart syndrome [74] and staged surgical-catheter approach [79,80] to accomplish staged Fontan need further study.

Conclusions

The efficacy of stents in the management of vascular obstructive lesions not responsive to balloon angioplasty is well accepted. The feasibility, safety and effectiveness in successfully addressing branch pulmonary artery stenosis, aortic coarctation, right ventricular outflow tract constricts and systemic venous obstructive lesions have been validated. Stents may be useful in maintaining patency of ductus arteriosus and foramen ovale and surgically created aortopulmonary shunts. Newer generations of stents and simplified technique of implantation of stents have reduced complications. Stent therapy for pulmonary venous obstructive lesions, addressing growth related issues in children with biodegradable and growth stents and role of stents in hybrid procedures need further investigation.

References

1. Rao PS (2011) Balloon valvuloplasty and angioplasty in pediatric practice. Pediatric Therapeut 1: e103.
2. Rao PS (2012) Percutaneous occlusion of cardiac defects in children. Pediatric Therapeut 2: e107.
3. O’Laughlin MP, Perry SB, Lock JE, Mullins CE (1991) Use of endovascular stents in congenital heart disease. Circulation 83: 1923-1939.
4. Hijiya ZA, Al-Fadley F, Geggel RL, Marx GR, Galal O, et al. (1996) Stent implantation for relief of pulmonary artery stenosis: immediate and short-term results. Cathet Cardiovasc Diag 38: 16-23.
5. Shaffer KM, Mullins CE, Grifka RG, O’Laughlin MP, McMahon W, et al. (1998) Intravascular stents in congenital heart disease: short- and long-term results from a large single-center experience. J Am Coll Cardiol 31: 661-667.
6. Chatelain P, Meier B, Friedli B (1991) Stenting of superior vena cava and inferior vena cava for symptomatic narrowing after repeated atrial surgery for D-transposition of the great vessels. Br Heart J 66: 466-469.
7. Brown SC, Eykens B, Mertens L, Stockx L, Dumoulin M, et al. (1998) Self expandable stents for relief of venous baffle obstruction after the Mustard operation. Heart 79: 230-233.
8. Hosking MC, Murdison KA, Duncan WJ (1994) Transcatheter stent implantation for recurrent pulmonary venous pathway obstruction after the Mustard procedure. Br Heart J 72: 85-88.
9. Suárez de Lezo J, Pan M, Romero M, Medina A, Segura J, et al. (1995) Balloon-expandable stent repair of severe coarctation of aorta. Am Heart J 129: 1002-1008.
10. Hosking MC, Benson LN, Nakanishi T, Burrows PE, Williams WG, et al. (1992) Intravascular stent prosthesis for right ventricular outflow obstruction. J Am Coll Cardiol 20: 373-380.
11. Gribbs JL, Rothman MT, Rees MR, Parsons JM, Blackburn ME, et al. (1992) Stenting of the arterial duct: a new approach to palliation for pulmonary atresia. Br Heart J 67: 240-245.
12. Siblini G, Rao PS, Singh GK, Tinker K, Balfour IC (1997) Transcatheter management of neonates with pulmonary atresia and intact ventricular septum. Cathet Cardiovasc Diag 42: 395-402.
13. Ruiz CE, Gamra H, Zhang HP, Garcia EJ, Boucek MM (1993) Brief report: stenting of the ductus arteriosus as a bridge to cardiac transplantation in infants with the hypoplastic left-heart syndrome. N Engl J Med 328: 1605-1608.
14. Brown SC, Eykens B, Mertens L, Dumoulin M, Gewillig M (1998) Percutaneous treatment of stenosed major aortopulmonary collaterals with balloon dilatation and stenting: what can be achieved? Heart 79: 24-28.
15. El-Said HG, Clapp S, Fagan TE, Conwell J, Nihill MR (2000) Stenting of stenosed aortopulmonary collaterals and shunts for palliation of pulmonary atresia/ventricular septal defect. Catheter Cardiovasc Interv 49: 430-436.
16. Tsouinis E, Rao PS (2010) Stent therapy for clotted Blalock-Taussig shunts. Congenital Heart Cardiol Today 8(7): 1-9.
17. Chandar JS, Wolfe SB, Rao PS (1996) Role of Stents in the Management of Congenital Heart Defects. J Invasive Cardiol 8: 314-325.
18. Rao PS (1997) Stents in treatment of aortic coarctation. J Am Coll Cardiol 30: 1853-1855.
19. Rao PS (2001) Stents in the management of congenital heart disease in pediatric and adult patients. Indian Heart J 53: 714-730.
20. Rao PS (2003) Newer Stents in the Management of Vascular Stenoses in Children, In: Rao PS, Korn MJ (eds) Catheter Based Devices for Treatment of Noncoronary Cardiovascular Disease in Adults and Children. Lippincott, Williams & Wilkins, Philadelphia, PA.
21. Rao PS (2009) Stents in the management of aortic coarctation in young children. JACC Cardiovasc Interv 2: 884-886.
22. Sahu R, Rao PS (2012) Transcatheter stent therapy in children: An update. Pediatric Therapeut 5: 101.
23. Palmaz JC, Windeler SA, Garcia F, Tio FO, Sibbit RR, et al. (1986) Atherosclerotic rabbit aortas: expandable intraluminal grafting. Radiology 160: 723-726.
24. O’Laughlin MP, Slack MC, Grifka RG, Perry SB, Lock JE, et al. (1993) Implantation and intermediate-term follow-up of stents in congenital heart disease. Circulation 88: 605-614.
25. Fogelman R, Nykanen D, Smallhorn JF, McCrindle BW, Freedom RM, et al. (1995) Endovascular stents in the pulmonary circulation. Clinical impact on management and medium-term follow-up. Circulation 92: 881-885.
26. Rao PS, Balfour IC, Singh GK, Jureidini SB, Chen S (2001) Bridge stents in the management of obstructive vascular lesions in children. Am J Cardiol 88: 699-702.
27. Ing FF, Grifka RG, Nihill MR, Mullins CE (1995) Repeat dilation of intravascular stents in congenital heart defects. Circulation 92: 893-897.
28. Rao PS (1996) Aortic coarctation. In: Sigwart V, Bertrand M, Serruys PW (eds): Handbook of Cardiovascular Interventions, New York, NY, Churchill Livingstone: 757-781.
29. Rosenthal E, Qureshi SA, Tynan M (1995) Stent implantation for aortic recoarctation. Am Heart J 129: 1220-1221.
30. Bulbub ZR, Bruckheimer E, Love JC, Fahey JT, Hellenbrand WE (1996) Implantation of balloon-expandable stents for coarctation of the aorta: implantation data and short-term results. Cathet Cardiovasc Diag 39: 36-42.
31. Ebeid MR, Prieto LR, Latson LA (1997) Use of balloon-expandable stents for coarctation of the aorta: initial results and intermediate-term follow-up. J Am Coll Cardiol 30: 1847-1852.
32. Thanopoulos BV, Tripodakiadis F, Margetakis A, Mullins CE (1997) Long segment coarctation of the thoracic aorta: treatment with multiple balloon-expandable stent implantation. Am Heart J 133: 470-473.
33. Suárez de Lezo J, Pan M, Romero M, Medina A, Segura J, et al. (1999) Immediate and follow-up findings after stent treatment for severe coarctation of aorta. Am J Cardiol 83: 400-406.
34. Magee AG, Brzozinska-Rajszys G, Qureshi SA, Rosenthal E, Zubryczka M, et al. (1999) Stent implantation for aortic coarctation and recoarctation. Heart 82: 600-606.
35. Marshall AC, Perry SB, Keane JF, Lock JE (2000) Early results and medium-term follow-up of stent implantation for mild residual or recurrent aortic coarctation. Am Heart J 139: 1054-1060.
36. Thanopoulos BD, Hadjinkiolou LN, Konstadopoulou GN, Tsaoasis GS, Tripodakiadis F, et al. (2000) Stent implantation for coarctation of the aorta: intermediate term follow up and technical considerations. Heart 84: 65-70.
37. Hamdan MA, Maheshwari S, Fahey JT, Hellenbrand WE (2001) Endovascular stents for coarctation of the aorta: initial results and intermediate-term follow-up. J Am Coll Cardiol 38: 1518-1523.
38. Harrison DA, McLaughlin PR, Lazzam C, Connelly M, Benson LN (2001)
Endovascular stents in the management of coarctation of the aorta in the adolescent and adult: one year follow up. Heart 85: 561-566.
39. Ewert P, Berger F, Kreitschmair O, Nürnberg JH, Stiller B, et al. (2003) [Stent implantation as therapy of first choice in adults with coarctation]. Z Kardiol 92: 48-52.
40. Tyagi S, Singh S, Mukhopadhyay S, Kaul UA (2003) Self- and balloon-expandable stent implantation for severe native coarctation of aorta in adults. Am J Heart J 146: 920-928.
41. Haas NA, Lewin MA, Knirsch W, Nossal R, Ocker V, et al. (2005) Initial experience using the NuMED Cheatham Platinum (CP) stent for interventional treatment of coarctation of the aorta in children and adolescents. Z Kardiol 94: 113-120.
42. Golden AB, Hellenbrand WE (2007) Coarctation of the aorta: stenting in children and adults. Catheter Cardiovasc Interv 69: 289-299.
43. Qureshi AM, McElhinney DB, Lock JE, Lanzdorff MJ, Lang P, et al. (2007) Acute and intermediate outcomes, and evaluation of injury to the aortic wall, as based on 15 years experience of implanting stents to treat aortic coarctation. Cardiol Young 17: 307-318.
44. Weber HS, Cyran SE (2008) Endovascular stenting for native coarctation of the aorta is an effective alternative to surgical intervention in older children. Congenit Heart Dis 3: 54-59.
45. Holzer RJ, Chisolm JL, Hill SL, Cheatham JP (2008) Stenting complex aortic arch obstructions. Catheter Cardiovasc Interv 71: 375-382.
46. Musco C, Cifarelli A, Pucci E, Paladini S, De Felice F, et al. (2008) Endovascular treatment of aortic coarctation: long-term effects on hypertension. Int J Cardiol 130: 420-425.
47. Erdem A, Akderiz C, SarAstaAY T, Erol N, Demir F, et al. (2011) Cheatham-Platinum stent for native and recurrent aortic coarctation in children and adults: immediate and early follow-up results. Anadolu Kardiyol Derg 11: 441-449.
48. Krasemann T, Bano M, Rosenthal E, Qureshi SA (2011) Results of stent implantation for native and recurrent coarctation of the aorta-follow-up of up to 13 years. Catheter Cardiovasc Interv 75: 405-412.
49. Forbes TJ, Kim DW, Du W, Turner DR, Holzer R, et al. (2011) Comparison of surgical, stent, and balloon angioplasty treatment of native coarctation of the aorta: an observational study by the CCISC (Congenital Cardiovascular Interventional Study Consortium). J Am Coll Cardiol 58: 2664-2674.
50. Al-Ata J, Arfi AM, Hussain A, Kouatly A, Galal MO (2007) Stent angioplasty: an effective alternative in selected infants with critical native aortic coarctation. Pediatr Cardiol 28: 183-192.
51. Schaeffer R, Kolax T, Hesse C, Peuster M (2007) Implantation of stents for treatment of recurrent and native coarctation in children weighing less than 20 kilograms. Cardiol Young 17: 617-622.
52. Mohan UR, Danon S, Levi D, Connolly D, Moore JW (2009) Stent implantation for coarctation of the aorta in children <30 kg. JACC Cardiovasc Interv 2: 877-883.
53. Francis E, Gayathri S, Vaidyanathan B, Kannan BR, Kumar RK (2009) Emergency balloon dilation or stenting of critical coarctation of aorta in newborns and infants: An effective interim palliation. Ann Pediatr Cardiol 2: 111-115.
54. Rao PS (2009) Transcatheter interventions in critically ill neonates and infants with aortic coarctation. Ann Pediatr Cardiol 2: 116-119.
55. Rao PS (1993) Balloon dilation of stenotic bioprosthetic valves. In: Rao PS (ed): Transcatheter Therapy in Pediatric Cardiology, Wiley-Liss, New York, NY, 255-274.
56. Nakashishi T, Kondo C, Nishikawa T, Satomi G, Nakazawa M, et al. (1994) Intravascular stents for management of pulmonary artery and right ventricular outflow obstruction. Heart Vessels 9: 40-48.
57. Powell AJ, Lock JE, Keane JF, Perry SB (1995) Prolongation of RV-PA conduit life span by percutaneous stent implantation. Intermediate-term results. Circulation 92: 3282-3288.
58. Osvart C, Caldarone CA, McCrindle BW, Nykanen D, Freedom RM, et al. (1999) Endovascular stent implantation for the management of postoperative right ventricular outflow tract obstruction: clinical efficacy. J Thorac Cardiovasc Surg 118: 886-893.
59. Sugiyama H, Williams W, Benson LN (2005) Implantation of endovascular stents for the obstructive right ventricular outflow tract. Heart 91: 1058-1063.
60. Zeidenweber CM, Kim DW, Vincent RN (2007) Right ventricular outflow tract and pulmonary artery stents in children under 18 months of age. Catheter Cardiovasc Interv 69: 23-27.
61. Aggarwal S, Garekar S, Forbes TJ, Turner DR (2007) Is stent placement effective for palliation of right ventricle to pulmonary artery conduit stenosis? J Am Coll Cardiol 48: 480-484.
62. Maheshwari S, Bruckmeier E, Nehgme RA, Fehay JT, Khohwadala D, et al. (1997) Single coronary artery complicating stent implantation for homograft stenosis in tetralogy of Fallot. Cathet Cardiovasc Diagn 42: 405-407.
63. Hijazi ZM (1997) Interventionalists: watch out for coronary arterial anomalies in tetralogy of Fallot. Cathet Cardiovasc Diagn 42: 408.
64. Laudito A, Bandisodi VM, Lucas JP, Radtke WA, Adamson WT, et al. (2006) Right ventricular outflow tract stent as a bridge to surgery in a premature infant with tetralogy of Fallot. Ann Thorac Surg 81: 744-746.
65. Dohlen G, Chaturvedi RR, Benson LN, Ozawa A, Van Arsdel GS, et al. (2009) Stenting of the right ventricular outflow tract in the symptomatic infant with tetralogy of Fallot. Heart 95: 142-147.
66. Morgan GJ (2012) Echocardiographic Guidance for Neonatal RightVentricularOutflowTractStentImplantation.Congent Heart Dis.
67. Petit CJ, Gillespie MJ, Kreutzer J, Rome JJ (2006) Endovascular stents for relief of cyanosis in single-ventricle patients with shunt or conduit-dependent pulmonary blood flow. Catheter Cardiovasc Interv 68: 280-286.
68. Eicken A, Genz T, Sebening W (2006) Stenting of stenosed shunts in patients after a Norwood-Sano operation. Catheter Cardiovasc Interv 68: 301-303.
69. Kaestner M, Handke RP, Photiadis J, Sigler M, Schneider MB (2008) Implantation of stents as an alternative to reoperation in neonates and infants with acute complications after surgical creation of a systemic-to-pulmonary arterial shunt. Cardiol Young 18: 177-184.
70. Bonhoeffer P, Boudjemline Y, Saliba Z, Merckx J, Aggoun Y, et al. (2000) Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet 356: 1403-1405.
71. Lurz P, Bonhoeffer P, Taylor AM (2009) Percutaneous pulmonary valve implantation: an update. Expert Rev Cardiovasc Ther 7: 823-833.
72. McElhinney DB, Hellenbrand WE, Zahn EM, Jones TK, Cheatham JP, et al. (2010) Short- and medium-term outcomes after transcatheter pulmonary valve placement in the expanded multicenter US melody valve trial. Circulation 122: 507-516.
73. Ahl M, Choo KK, Latiff HA, Kanavelli G, Samion H, et al. (2004) Initial results and medium-term follow-up of stent implantation of patent ductus arteriosus in duct-dependent pulmonary circulation. J Am Coll Cardiol 44: 438-445.
74. Galantowicz M, Cheatham JP (2005) Lessons learned from the development of a new hybrid strategy for the management of hypoplastic left heart syndrome [published correction appears in Pediatr Cardiol 26: 190 –199.
75. Schranz D, Zartner P, Michel-Behnke I, Akintürk H (2006) Bioabsorbable metal stents for percutaneous treatment of critical recoarctation of the aorta in a newborn. Catheter Cardiovasc Interv 67: 671-673.
76. Ewert P, Peters B, Nagdyman N, Miera O, Kühne T, et al. (2008) Early and midterm results with the Growth Stent–a possible concept for transcatheter treatment of aortic coarctation from infancy to adulthood by stent implantation? Catheter Cardiovasc Interv 71: 120-126.
77. Dragulescu A, Ghez O, Quilici J, Fraisse A (2009) Paclitaxel-drug-eluting stent placement for pulmonary vein stenosis as a bridge to heart-lung transplantation. Pediatr Cardiol 30: 1169-1171.
78. Mueller GC, Dodge-Khatami A, Weil J (2010) First experience with a new drug-eluting balloon for the treatment of congenital pulmonary vein stenosis in a neonate. Cardiol Young 20: 455-458.
79. Konertz W, Schneider M, Herwig V, Kampmann C, Waldenberger F, et al. (1995) Modified hemi-Fontan operation and subsequent nonsurgical Fontan completion. J Thorac Cardiovasc Surg 110: 865-867.
80. Hausdorf G, Schneider M, Konertz W (1996) Surgical preconditioning and completion of total cavopulmonary connection by interventional cardiac catheterisation: a new concept. Heart 75: 403-409.